The synergistic blockade of the key platelet signaling pathways of cyclooxygenase-1
blockade and P2Y12 signaling by combining aspirin plus a potent P2Y12 inhibitor …

Coronary artery disease (CAD) is one of the leading causes of death globally, and
antiplatelet therapy is crucial for both its prevention and treatment. Antiplatelet drugs such as …

Background Carriers of cytochrome 2C19 (CYP2C19) loss-of-function (LoF) alleles treated
with clopidogrel have impaired drug metabolism, resulting in reduced active metabolite …

Antithrombotic therapy after cardiac percutaneous interventions is key for the prevention of
thrombotic events but is inevitably associated with increased bleeding, proportional to the …

Dual antiplatelet therapy (DAPT) is the gold standard after acute coronary syndromes (ACS)
or chronic coronary syndromes (CCS) undergoing percutaneous coronary intervention …

Current evidence indicates that dual antiplatelet therapy with aspirin plus a P2Y12 inhibitor
is essential for the prevention of thrombotic events after percutaneous coronary …

Background Among patients treated with a novel oral anticoagulant (NOAC) undergoing
percutaneous coronary intervention (PCI), combination therapy with clopidogrel (ie, known …

Abstract Aims Randomized controlled trials (RCTs) testing bleeding reduction strategies
using antiplatelet treatment regimens (BRATs) in acute coronary syndromes (ACS) have …

Aims Ticagrelor is associated with a lower risk of ischemic events than clopidogrel.
However, it is uncertain whether the benefits of more intensive anti-ischemic therapy …

Introduction In patients with acute coronary syndrome (ACS), the ischemic benefit of
antithrombotic treatment is counterbalanced by the risk of bleeding. The recognition that …